Abbott Laboratories (ABT) 44.95 $ABT
TMVR Market - Medtronic, Abbott Laboratories, Inc & Edward Lifesciences Corporation Lead Transcatheter Mitral Valve Replacement Industry
PR Newswire Europe - Wed Aug 03, 11:45AM CDT
PUNE, India, August 3, 2016 /PRNewswire/ --
ABT: 44.95 (-0.12), MDT: 86.67 (-0.97)
Abbott Unveils Alinity(TM), its Unified Family of Innovative Next-Generation Diagnostics Systems
PR Newswire Europe - Tue Aug 02, 9:00AM CDT
Abbott announced today the introduction of Alinity(TM), its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
ABT: 44.95 (-0.12)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.21 (+1.49), ABT: 44.95 (-0.12), ICPT: 172.59 (+2.12), EXEL: 9.39 (+0.24)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $45.57
Comtex SmarTrend(R) - Mon Aug 01, 9:13AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $44.71 and have already reached the first level of resistance at $45.16. Should the shares continue to rise, the resistance pivots of $45.57 and $46.43 will be of interest.
ABT: 44.95 (-0.12)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVLS: 4.83 (+0.02), CYTR: 0.61 (+0.04), CEMP: 22.20 (+2.04), ACUR: 1.88 (+0.04), NVS: 82.40 (-0.56)
Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 44.95 (-0.12), CYBR: 56.15 (+1.25), BAC: 14.48 (+0.35), ARIA: 9.93 (+0.21), X: 26.20 (+0.51)
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Thu Jul 28, 11:54AM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.93 to a high of $45.16. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $43.90 on volume of 9.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.95 (-0.12)
Abbott Laboratories (ABT) Breaks Through Resistance at $43.97
Comtex SmarTrend(R) - Thu Jul 28, 8:42AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $43.60 today and has reached the first level of resistance at $43.97. Analysts will be watching for a cross of the next upside pivot targets of $44.26 and $44.92.
ABT: 44.95 (-0.12)
Q2 Earnings Season Coming Up Roses
Mark Vickery - ZACKS - Wed Jul 20, 5:12AM CDT
Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.
ABT: 44.95 (-0.12), EBAY: 30.95 (+0.16), QCOM: 61.01 (+0.41), HAL: 42.94 (+0.88), INTC: 34.25 (-0.31), MSFT: 56.97 (+0.39), UAL: 44.90 (+0.50), MS: 28.42 (+0.42)
Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVS: 82.40 (-0.56)
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 44.95 (-0.12), INSY: 17.85 (+2.65), GWPH: 95.02 (+0.95), PFE: 35.29 (-1.10)
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 23.84 (-0.33), ABT: 44.95 (-0.12), ALR: 37.24 (+0.65), NUVA: 62.76 (+0.13)
Why is Alere Inc. (ALR) up Today?
Afrasiab Mian - Zacks Investment Research - Fri Jul 15, 2:52PM CDT
Alere Inc. (ALR) is up 10.5% in afternoon trading on Friday after analysts saw an increased likelihood that the company's $5.8 billion acquisition by Abbott Laboratories (ABT) would close.
ABT: 44.95 (-0.12), ALR: 37.24 (+0.65)
Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:25AM CDT
Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), INVA: 13.01 (+0.17), LLY: 82.72 (-0.60)
Learn how to target a 20% return on Gilead Sciences, or get option-trade ideas on Aetna, Exelixis, Priceline and Abbott Laboratories or any stock you choose
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, AET, EXEL, GILD, and PCLN.
ABT: 44.95 (-0.12), GILD: 80.09 (+0.52), AET: 116.86 (+1.15), PCLN: 1,371.14 (+25.76), EXEL: 9.39 (+0.24)
Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 8:30AM CDT
Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
ABT: 44.95 (-0.12), SNN: 33.20 (-0.28), JNJ: 123.90 (-0.95), MDT: 86.67 (-0.97), STJ: 83.53 (+0.01)
TMVR Market - Medtronic, Abbott Laboratories, Inc & Edward Lifesciences Corporation Lead Transcatheter Mitral Valve Replacement Industry
PR Newswire Europe - Wed Aug 03, 11:45AM CDT
PUNE, India, August 3, 2016 /PRNewswire/ --
ABT: 44.95 (-0.12), MDT: 86.67 (-0.97)
Abbott Unveils Alinity(TM), its Unified Family of Innovative Next-Generation Diagnostics Systems
PR Newswire Europe - Tue Aug 02, 9:00AM CDT
Abbott announced today the introduction of Alinity(TM), its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
ABT: 44.95 (-0.12)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.21 (+1.49), ABT: 44.95 (-0.12), ICPT: 172.59 (+2.12), EXEL: 9.39 (+0.24)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $45.57
Comtex SmarTrend(R) - Mon Aug 01, 9:13AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today above their pivot of $44.71 and have already reached the first level of resistance at $45.16. Should the shares continue to rise, the resistance pivots of $45.57 and $46.43 will be of interest.
ABT: 44.95 (-0.12)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)
What Awaits ACUR & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:43AM CDT
Medical is one of the six sectors that are projected to record positive earnings growth this quarter.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVLS: 4.83 (+0.02), CYTR: 0.61 (+0.04), CEMP: 22.20 (+2.04), ACUR: 1.88 (+0.04), NVS: 82.40 (-0.56)
Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 44.95 (-0.12), CYBR: 56.15 (+1.25), BAC: 14.48 (+0.35), ARIA: 9.93 (+0.21), X: 26.20 (+0.51)
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.05% Rise
Comtex SmarTrend(R) - Thu Jul 28, 11:54AM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.93 to a high of $45.16. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $43.90 on volume of 9.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 44.95 (-0.12)
Abbott Laboratories (ABT) Breaks Through Resistance at $43.97
Comtex SmarTrend(R) - Thu Jul 28, 8:42AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $43.60 today and has reached the first level of resistance at $43.97. Analysts will be watching for a cross of the next upside pivot targets of $44.26 and $44.92.
ABT: 44.95 (-0.12)
Q2 Earnings Season Coming Up Roses
Mark Vickery - ZACKS - Wed Jul 20, 5:12AM CDT
Morgan Stanley, Abbott Labs and Halliburton all beat earnings expectations before the opening bell today.
ABT: 44.95 (-0.12), EBAY: 30.95 (+0.16), QCOM: 61.01 (+0.41), HAL: 42.94 (+0.88), INTC: 34.25 (-0.31), MSFT: 56.97 (+0.39), UAL: 44.90 (+0.50), MS: 28.42 (+0.42)
Abbott Labs (ABT) Q2 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:37AM CDT
Abbott Laboratories (ABT) is scheduled to report second-quarter 2016 results before the opening bell on Jul 20.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), NVS: 82.40 (-0.56)
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 44.95 (-0.12), INSY: 17.85 (+2.65), GWPH: 95.02 (+0.95), PFE: 35.29 (-1.10)
Alere Updates on 10K Filing, Reports Preliminary Q1 Figures
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 3:24PM CDT
Alere Inc. (ALR) lowered revenue estimate for the year that ended on Dec 31, 2015 and also offered some Q1 figures.
BSX: 23.84 (-0.33), ABT: 44.95 (-0.12), ALR: 37.24 (+0.65), NUVA: 62.76 (+0.13)
Why is Alere Inc. (ALR) up Today?
Afrasiab Mian - Zacks Investment Research - Fri Jul 15, 2:52PM CDT
Alere Inc. (ALR) is up 10.5% in afternoon trading on Friday after analysts saw an increased likelihood that the company's $5.8 billion acquisition by Abbott Laboratories (ABT) would close.
ABT: 44.95 (-0.12), ALR: 37.24 (+0.65)
Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:25AM CDT
Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), INVA: 13.01 (+0.17), LLY: 82.72 (-0.60)
Learn how to target a 20% return on Gilead Sciences, or get option-trade ideas on Aetna, Exelixis, Priceline and Abbott Laboratories or any stock you choose
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, AET, EXEL, GILD, and PCLN.
ABT: 44.95 (-0.12), GILD: 80.09 (+0.52), AET: 116.86 (+1.15), PCLN: 1,371.14 (+25.76), EXEL: 9.39 (+0.24)
Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 8:30AM CDT
Zacks Industry Outlook Highlights: Johnson & Johnson, Smith & Nephew, Medtronic, Abbott Laboratories and St. Jude Medical
ABT: 44.95 (-0.12), SNN: 33.20 (-0.28), JNJ: 123.90 (-0.95), MDT: 86.67 (-0.97), STJ: 83.53 (+0.01)
